[10] Recent therapeutics strategies have prioritized incretin-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide (Ozempic , Wegovy ) and liraglutide (Victoza ), which improve glycemic control, reduce glycated hemoglobin (HbA1c), and promote weight loss
Research has shown that higher levels of carnitine in the muscles are associated with improved fat metabolism and increased endurance performance (1, 2, 3)
These figures matter because they reflect how consistently the compound works across different individuals, not just how well it works for the average participant
These medications help regulate appetite, slow stomach emptying, and stimulate insulin production in response to meals
Individual patient factors : Those with pre-existing gastroparesis, a history of gastrointestinal disorders, or heightened sensitivity to medications may be at increased risk
For patients with poor glycemic control who stop GLP-1, monitor glucose closely and use short-acting insulin protocols to avoid hyperglycemia